Implementation of Clinical Proteomics: A Step Closer to Personalized Medicine?

Vlahou, Antonia

doi:10.1002/prca.201800088

Cited by 10 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another issue is the paucity of studies on in‐depth analysis of single‐tear samples, which are hindered by the limited sample amounts. However, diagnostics and treatment in modern medicine have been progressively focusing on disease subtyping and patient stratification, based on better‐defined and better‐integrated omics profiles (Vlahou, 2019). Such a level of molecular profiling can guide personalized evaluation within a given physio‐pathological state.…”

Section: Discussionmentioning

confidence: 99%

Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

Ponzini

Santambrogio

Palma

et al. 2021

Mass Spectrometry Reviews

View full text Add to dashboard Cite

The lacrimal film has attracted increasing interest in the last decades as a potential source of biomarkers of physiopathological states, due to its accessibility, moderate complexity, and responsiveness to ocular and systemic diseases. High‐performance liquid chromatography‐mass spectrometry (LC‐MS) has led to effective approaches to tear proteomics, despite the intrinsic limitations in sample amounts. This review focuses on the recent progress in strategy and technology, with an emphasis on the potential for personalized medicine. After an introduction on lacrimal‐film composition, examples of applications to biomarker discovery are discussed, comparing approaches based on pooled‐sample and single‐tear analysis. Then, the most critical steps of the experimental pipeline, that is, tear collection, sample fractionation, and LC‐MS implementation, are discussed with reference to proteome‐coverage optimization. Advantages and challenges of the alternative procedures are highlighted. Despite the still limited number of studies, tear quantitative proteomics, including single‐tear investigation, could offer unique contributions to the identification of low‐invasiveness, sustained‐accessibility biomarkers, and to the development of personalized approaches to therapy and diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

Ponzini

Santambrogio

Palma

et al. 2021

Mass Spectrometry Reviews

View full text Add to dashboard Cite

show abstract

“…Additionally, the integration of proteomic biomarkers into clinical decision-making algorithms and risk assessment models may improve the accuracy of osteoporosis diagnosis, fracture prediction, and treatment selection. Finally, the implementation of personalized medicine approaches based on proteomic profiling may enable tailored interventions targeting individual patient needs and disease characteristics, ultimately improving patient outcomes and reducing the burden of osteoporosis-related fractures [163,164].…”

Section: Future Directions and Potential Impact On Clinical Practicementioning

confidence: 99%

Proteomic Insights into Osteoporosis: Unraveling Diagnostic Markers and Therapeutic Targets for the Metabolic Bone Disease

Wang,

Xue,

et al. 2024

Preprint

View full text Add to dashboard Cite

Osteoporosis (OP), a prevalent skeletal disorder characterized by compromised bone strength and increased susceptibility to fractures, poses a significant public health concern. This review aims to provide a comprehensive analysis of the current state of research in the field, focusing on the application of proteomic techniques to elucidate diagnostic markers and therapeutic targets for OP. The integration of cutting-edge proteomic technologies has enabled the identification and quantification of proteins associated with bone metabolism, leading to a deeper understanding of the molecular mechanisms underlying OP. In this review, we systematically examine recent advancements in proteomic studies related to OP, emphasizing the identification of potential biomarkers for OP diagnosis and the discovery of novel therapeutic targets. Additionally, we discuss the challenges and future directions in the field, highlighting the potential impact of proteomic research in transforming the landscape of OP diagnosis and treatment.

show abstract

“…The emerging concept of personalized medicine relies on global and integrative approaches (such as proteomic technologies) to provide more precise patient care, and these technologies can also provide valuable information about the diseases [ 14 , 15 ]. The application of proteomic techniques to diseases is known as clinical proteomics.…”

Section: Proteomic Strategiesmentioning

confidence: 99%

Proteomics in Inherited Metabolic Disorders

Chantada-Vázquez

Bravo

Gouveia

et al. 2022

IJMS

View full text Add to dashboard Cite

Inherited metabolic disorders (IMD) are rare medical conditions caused by genetic defects that interfere with the body’s metabolism. The clinical phenotype is highly variable and can present at any age, although it more often manifests in childhood. The number of treatable IMDs has increased in recent years, making early diagnosis and a better understanding of the natural history of the disease more important than ever. In this review, we discuss the main challenges faced in applying proteomics to the study of IMDs, and the key advances achieved in this field using tandem mass spectrometry (MS/MS). This technology enables the analysis of large numbers of proteins in different body fluids (serum, plasma, urine, saliva, tears) with a single analysis of each sample, and can even be applied to dried samples. MS/MS has thus emerged as the tool of choice for proteome characterization and has provided new insights into many diseases and biological systems. In the last 10 years, sequential window acquisition of all theoretical fragmentation spectra mass spectrometry (SWATH-MS) has emerged as an accurate, high-resolution technique for the identification and quantification of proteins differentially expressed between healthy controls and IMD patients. Proteomics is a particularly promising approach to help obtain more information on rare genetic diseases, including identification of biomarkers to aid early diagnosis and better understanding of the underlying pathophysiology to guide the development of new therapies. Here, we summarize new and emerging proteomic technologies and discuss current uses and limitations of this approach to identify and quantify proteins. Moreover, we describe the use of proteomics to identify the mechanisms regulating complex IMD phenotypes; an area of research essential to better understand these rare disorders and many other human diseases.

show abstract

Implementation of Clinical Proteomics: A Step Closer to Personalized Medicine?

Cited by 10 publications

References 31 publications

Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

Proteomic Insights into Osteoporosis: Unraveling Diagnostic Markers and Therapeutic Targets for the Metabolic Bone Disease

Proteomics in Inherited Metabolic Disorders

Contact Info

Product

Resources

About